Fed Ghali (@fedghali) 's Twitter Profile
Fed Ghali

@fedghali

ID: 944057204683915266

calendar_today22-12-2017 04:09:12

112 Tweet

288 Followers

345 Following

Fed Ghali (@fedghali) 's Twitter Profile Photo

Special weekend honoring the remarkable career of Dr. Weiss (Yale Urology), and bonus seeing one of my own mentors Ithaar H. Derweesh give a fantastic talk on the expanding role of multimodal/surgical care in advanced kidney cancer - all in our most elegant attire of course

Special weekend honoring the remarkable career of Dr. Weiss (<a href="/Yale_Urology/">Yale Urology</a>), and bonus seeing one of my own mentors <a href="/Cold_Steel_1970/">Ithaar H. Derweesh</a> give a fantastic talk on the expanding role of multimodal/surgical care in advanced kidney cancer - all in our most elegant attire of course
Fed Ghali (@fedghali) 's Twitter Profile Photo

Important points. Highlighting technical/ethical challenges we need to face in oncology trials, and very applicable to NMIBC in particular.

Fed Ghali (@fedghali) 's Twitter Profile Photo

Great turn out at fundraising event for Bladder Cancer Advocacy Network Walk, with Yale Urology RNs, APRNs, residents, faculty, and friends showing up to support a great cause Catch the Bladder Bulldogs at the BCAN walk in NYC next week!

Great turn out at fundraising event for <a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> Walk, with <a href="/Yale_Urology/">Yale Urology</a> RNs, APRNs, residents, faculty, and friends showing up to support a great cause

Catch the Bladder Bulldogs at the BCAN walk in NYC next week!
Bishal Gyawali, MD, PhD, FASCO (@oncology_bg) 's Twitter Profile Photo

A bombshell of an article just published in JAMA Oncology by Cary Gross Yale COPPER Center and other colleagues. What a clever and smart way to look into this question. Read to see what I mean. Congratulations to all authors. jamanetwork.com/journals/jamao…

UroToday.com (@urotoday) 's Twitter Profile Photo

AIM High: Epigenetic modulation and immune stimulation in #BladderCancer - Elizabeth Koehne University of Washington and Sam S. Chang MD, MBA Vanderbilt Urology discuss her research and the potential of making bladder cancer more susceptible to IO by reversing epigenetic mechanisms > bit.ly/3V9Lcla

AIM High: Epigenetic modulation and immune stimulation in #BladderCancer - Elizabeth Koehne <a href="/UW/">University of Washington</a> and <a href="/UroCancerMD/">Sam S. Chang MD, MBA</a> <a href="/VUMCurology/">Vanderbilt Urology</a> discuss her research and the potential of making bladder cancer more susceptible to IO by reversing epigenetic mechanisms &gt; bit.ly/3V9Lcla
Fed Ghali (@fedghali) 's Twitter Profile Photo

Fantastic time at the Bladder Cancer Advocacy Network Walk in New York this weekend with the Yale Urology team! Lucky to work with this group and show support for the bladder cancer patients we treat

Fantastic time at the <a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> Walk in New York this weekend with the <a href="/Yale_Urology/">Yale Urology</a> team!

Lucky to work with this group and show support for the bladder cancer patients we treat
Yale Urology (@yale_urology) 's Twitter Profile Photo

Consider this your personal invitation to our destination CME event, Bulldog Debates! [happening Nov. 2-3 in NYC] The deadline to register is Oct. 18➡️medicine.yale.edu/urology/event/… Yale School of Medicine|Chester Koh, MD, MBA|Curtis Pettaway, MD|Landon Trost, MD|shonig|Angela Arlen|Urology Times

JAMA Oncology (@jamaonc) 's Twitter Profile Photo

An analysis of cancer drugs granted accelerated approval in the US revealed that two-thirds were also approved in the EU, and nearly half of those lack a verified clinical benefit in terms of overall survival or quality of life. ja.ma/4fqMHDm

An analysis of cancer drugs granted accelerated approval in the US revealed that two-thirds were also approved in the EU, and nearly half of those lack a verified clinical benefit in terms of overall survival or quality of life. ja.ma/4fqMHDm
Bishal Gyawali, MD, PhD, FASCO (@oncology_bg) 's Twitter Profile Photo

The reason we are having all these “debates” is because the regulators didn’t mandate the industry to conduct proper trials teasing out the relative contributions of adjuvant versus neoadjuvant components. nature.com/articles/s4157…

Fed Ghali (@fedghali) 's Twitter Profile Photo

A real privilege talking with Sam S. Chang MD, MBA and summarizing a longer argument I laid out at SUO - there may be a key role for local therapy in metUC patients responding to new therapies. We'll be studying this prospectively Yale Urology soon!

European Urology (@euplatinum) 's Twitter Profile Photo

🧠 Words matter in science. 📢 In their @EUPlatinum article, Vickers & Inman call for stricter labeling of clinical trials: ❌ Don't call single-arm studies “phase 3” ❌ Don’t mix “registrational” with “phase 2” ✅ Let’s keep trial terminology precise—for better science &

🧠 Words matter in science.

📢 In their @EUPlatinum article, Vickers &amp; Inman call for stricter labeling of clinical trials:
❌ Don't call single-arm studies “phase 3”
❌ Don’t mix “registrational” with “phase 2”

✅ Let’s keep trial terminology precise—for better science &amp;